目的 觀察疏風解毒膠囊治療急性咽炎風熱證的臨床療效及安全性。方法 將120 例急性咽炎風熱證患者隨機分為治療組及對照組，各60 例。治療組口服疏風解毒膠囊4 粒/次、3 次/d，對照組服用清開靈軟膠囊2 粒/次、3 次/d，療程均為5 d。觀察治療前后咽痛、咽部黏膜充血程度及咽干、灼熱等主次癥的改善程度及積分變化。結(jié)果 治療組痊愈35 例，總有效率96.67%；對照組痊愈29 例，總有效率86.67%，兩組療效比較差異有統(tǒng)計學意義（P <0.05）。咽痛主癥VAS 評分，治療組減（5.56±1.82）分，對照組減（3.00±2.27）分，兩組相比差異有統(tǒng)計學意義（P <0.05）。不良反應發(fā)生率，治療組為1.67%，對照組為3.33%。結(jié)論 疏風解毒膠囊對治療急性咽炎風熱證療效確切，且不良反應少，可供臨床推廣應用。

Objective To explore the clinical effect and safety of Shufeng Jiedu Capsule on the acute pharyngitis. Methods Patients with acute pharyngitis (120 cases) were randomly divided into two groups with treatment duration of 5 d (60 cases by Shufeng Jiedu Capsule 4#/d tid, and 60 cases by Qingkailing Soft Capsule 2#/d tid ). The improvement and integral change of sore throat, tunica mucosa pharyngis congestion and dry throat, burning and other primary and secondary disease were observed before and after the treatment. Results The total effective rates of treatment and control groups were 96.67% and 86.66%, respectively, with significant difference between the two groups (P < 0.05). The improvement of sore throat in treatment and control groups were 5.56 ± 1.82 and 3.00 ± 2.27, with significant difference between the two groups (P < 0.05). The adverse reaction rates in treatment and control groups were 1.67% and 3.34%, respectively. Conclusion Shufeng Jiedu Capsule has a better efficacy for treating acute pharyngitis, and shows less side effect.